List view / Grid view
9 May 2011 | By Pfizer
Pfizer Inc. announced that the data from its two pivotal Phase 3 immunogenicity and safety trials of Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine...
5 May 2011 | By Pfizer
Pfizer Inc. announced that Revatio® (sildenafil citrate) has been approved by the European Commission...
25 April 2011 | By Pfizer Inc.
Pfizer has commented on an abstract concerning the ORAL Sync Phase 3 study of tofacitinib in patients with rheumatoid arthritis...
20 April 2011 | By Pfizer
Shanghai Pharmaceutical Co. Ltd. and Pfizer Inc. today announced the signing of a MOU...
15 April 2011 | By Pfizer
Pfizer Inc. announced top-line results from the ORAL Scan Phase 3 study (A3921044)...
11 April 2011 | By GDS International
Every other industry is getting on the social media bandwagon. But could social media actually prove beneficial to the world of pharma?...
11 April 2011 | By Citigate Dewe Rogerson Ltd
immatics, announced that Pfizer are to support its pivotal Phase III trial (IMPRINT) with IMA901...
28 March 2011 | By De Montfort University
De Montfort University’s unique QbD course received major endorsement by senior industry leaders when it was launched last week...
17 March 2011 | By GDS International
Personalised medicine is making a comeback – but will it stick this time?...
11 March 2011 | By PharmaChemical Ireland
PharmaChemical Ireland, welcomed the news that Amgen has agreed to purchase Pfizer’s manufacturing facility in Dun Laoghaire, Co Dublin...
10 March 2011 | By Pfizer
View and listen to a webcast of a presentation by Mikael Dolsten, President, Worldwide R&D...
1 March 2011 | By Pfizer
Pfizer completed its acquisition of King through the merger of its wholly owned subsidiary, Parker Tennessee Corp...
25 February 2011 | By GlaxoSmithKline
GSK, ViiV Healthcare, & Pfizer announced the appointment of David Redfern as the new Chairman of the Board for ViiV Healthcare...
14 February 2011 | By GDS International
What are the strategies for reducing drug attrition rates in the clinic through the application of transgenic rodent models?...
14 February 2011 | By Integra Communications Ltd
A significant number of new, innovative pharmaceutical companies could emerge from the releasing of talented Pfizer scientists...
